Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
abiraterone, absent, ABX, Adaptimmune, Affimed, allogeneic, androgen, antitumor, ANZUP, ASCO, Atara, atom, Atridia, Australian, baseline, beam, bear, Bellicum, beta, Bio, biochemical, Biomedizinische, BioNTech, Bluebird, bypassing, cabazitaxel, calendar, CAM, Celgene, Celyad, Chairman, chemically, choice, CMC, compassionate, conventional, cooperation, cooperative, deduction, differentiating, discretionary, distinct, distinctive, donor, dotted, drafting, energetic, enzalutamide, Erik, error, Evonik, exhaustion, Exit, fact, family, feedback, Forschungsreagenzien, GBq, German, Gilead, gradually, Heidelberg, hematoxicity, highest, highlighted, Hofman, immaterial, Immunocore, intangible, Intellia, intravenously, Intrexon, Isotopen, ITM, Kintor, legacy, lesser, lethal, lutetium, MacCallum, mandate, Marquette, MedImmune, Melbourne, modality, morale, multicenter, NAAD, neurotoxicity, Northwestern, optimum, osteosarcoma, overexpressed, paint, painted, palliative, particle, PCAOB, pilot, point, power, powerful, precursor, prove, provisional, Pty, radiographic, radioligand, RadioMedix, radiotherapy, refocused, regimen, remedial, renal, reorganization, rescue, residual, resold, retention, RLT, roughly, rounded, rulemaking, Scientist, SCRI, shelf, Shortly, Singapore, skeletal, skip, sublicensee, Suzhou, Sydney, symptomatic, syndrome, Takara, talent, Task, taxane, Technologien, TheraP, tiered, titration, travel, Trump, unclear, uncontrolled, unexpected, Unum, VISION, workforce, Zenith
Removed:
abandon, accessibility, accessible, acid, activated, ADC, addressed, adenocarcinoma, advancing, Africa, aggressively, aging, allocation, Amgen, aminopterin, Ann, antibody, Aplin, appeal, appointed, Argentina, ariad, arm, arthritic, attach, Avastin, avoiding, awarded, aware, back, background, Bank, Belgium, beneficially, bevacizumab, billion, biodistribution, biological, biologically, blood, bloodstream, BMS, Boehringer, bowel, brain, Brauer, Brinkley, broaden, burden, Canada, Canadian, carboplatin, Carolina, cellular, Chapel, characteristic, chemotherapeutic, China, circulating, cisplatin, Citigroup, classify, clearance, cleaved, closed, colon, colorectal, commitment, comparable, compartment, competitor, complaint, concentration, confirming, conjugated, connected, consistently, contrast, converted, costimulatory, counsel, County, curative, customized, DAVLBH, deeply, defendant, deficiency, delaying, dense, deprive, derivative, Derivatively, destabilizer, destruction, deterring, District, division, Dohme, dosed, dosing, doubt, doxorubicin, efficiently, Electric, emerged, employ, employing, encompassing, endometrial, endosomal, enriched, enrolling, epothilone, Eric, erlotinib, ESMO, essential, etanercept, extract, extracted, Fannie, featuring, fission, footnote, founded, FR, France, Fred, Freddie, guide, Hage, Hanham, Herceptin, Hill, Home, Hong, hybrid, hydrazide, ideal, iii, image, impractical, incidence, India, indiscriminate, Individually, inflammation, inflammatory, Ingelheim, inhibitor, inhibitory, injectable, intensity, internalization, intestine, inventoried, Israel, Italy, Jamele, JHP, John, judgment, Kappa, Keith, kidney, Kingdom, Kong, Kozin, largest, leading, Lesley, leveraging, linked, linker, linking, liposomal, liver, loan, lung, Mac, Mae, Marc, marked, maturing, MBA, meaningfully, medium, Meldrum, methotrexate, mice, microbiology, microtubule, Middleton, Mike, mitigate, modest, modular, modulate, module, molecular, monoclonal, monotherapy, Moore, MTD, mTOR, multinational, neovasculature, Nguyen, nivolumab, noise, nominal, nonpublic, North, November, NSCLC, nuclide, originating, paclitaxel, parallel, parent, payload, pediatric, pegylated, penetrate, pentanedioic, people, personalize, PFS, pharmacy, PKD, plaintiff, platinum, play, PLD, polycystic, polymerization, poor, posed, potency, preclinical, predefined, premium, prevalence, prevalent, preventing, progressed, projected, proteasome, Puma, purpose, quick, radioisotope, reader, realizing, recurrent, released, releasing, reliable, repeatedly, replaced, replacing, resolution, Revocable, rheumatoid, Rituxan, role, Rubin, Russell, salvage, scan, scanned, scheduled, selective, selectively, selectivity, shareholder, Sharp, shorter, signal, Similarly, simple, Situated, South, Southern, spacer, Spain, Squibb, stability, stable, step, structure, subgroup, subset, Suisse, superior, synthesize, Taiwan, Tc, technetium, termed, Tippecanoe, title, tolerated, topotecan, toxic, toxicology, transport, Trust, TubBH, tubulin, unconjugated, undelivered, understand, Underwriter, underwriting, untargeted, uptake, uranium, USA, usage, validate, validating, Vallabhaneni, Veloso, Venezuela, Verastem, viable, vitamin, vitro, vulnerability, weight, widespread, withdrew, worsening, xenograft
Filing tables
Filing exhibits
Related press release
ECYT similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-3 No. 333-220920; and Form S-8 Nos. 333-216675, 333-210035, 333-202792, 333-194366, 333-172121 and 333-190514) of Endocyte, Inc., and in the related Prospectus of our reports dated February 27, 2018, with respect to the consolidated financial statements of Endocyte, Inc., and the effectiveness of internal control over financial reporting of Endocyte, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ Ernst and Young LLP
Indianapolis, Indiana
February 27, 2018